Latest filing published 10 Jun 2025 for Aspire Biopharma Holdings, Inc., €3,244. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Donald G. Fell (senior executive) discloses dealings in 2 companies, chiefly Scienture Holdings, Inc. and Aspire-Lakewood Holdings, Inc. Between 4 May 2021 and 4 June 2025, the trades on record add up to 6 filings.
Every open-market trade on record is a purchase: 4 purchases worth €11k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. Since January 2025: 2 purchases and no sales on the market.
Half of the purchases are above €2,836 and half below. No cluster: in 3 purchases, no other insider of the company bought within 30 days.
The newest entry dates from 10 June 2025: an open-market purchase of €3,244, in Aspire-Lakewood Holdings, Inc. The median gap between a trade and its publication by SEC (Form 4) is 5 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations